Developing a Paper-Based Antigen Assay to Differentiate between Coronaviruses and SARS-CoV-2 Spike Variants.
Anal Chem
; 93(22): 7825-7832, 2021 06 08.
Article
in English
| MEDLINE | ID: covidwho-1243271
ABSTRACT
COVID-19 first appeared in December of 2019 in Wuhan, China. Since then, it has become a global pandemic. A robust and scalable diagnostics strategy is crucial for containing and monitoring the pandemic. RT-PCR is a known, reliable method for COVID-19 diagnostics, which can differentiate between SARS-CoV-2 and other viruses. However, PCR is location-dependent, time-consuming, and relatively expensive. Thus, there is a need for a more flexible method, which may be produced in an off-the-shelf format and distributed more widely. Paper-based immunoassays can fulfill this function. Here, we present the first steps toward a paper-based test, which can differentiate between different spike proteins of various coronaviruses, SARS-CoV-1, SARS-CoV-2, and CoV-HKU1, with negligible cross-reactivity for HCoV-OC43 and HCoV-229E in a single assay, which takes less than 30 min. Furthermore, our test can distinguish between fractions of the same spike protein. This is done by an altered assay design with four test line locations where each antigen builds a unique, identifiable binding pattern. The effect of several factors, such as running media, immunoprobe concentration, and antigen interference, is considered. We find that running media has a significant effect on the final binding pattern where human saliva provides results while human serum leads to the lowest signal quality.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Coronavirus OC43, Human
/
COVID-19
Type of study:
Randomized controlled trials
Topics:
Variants
Limits:
Humans
Country/Region as subject:
Asia
Language:
English
Journal:
Anal Chem
Year:
2021
Document Type:
Article
Affiliation country:
Acs.analchem.0c05438
Similar
MEDLINE
...
LILACS
LIS